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ABSTRACT
ISAba1-like sequences were identiﬁed immediately upstream of the blaampC gene in ceftazidime-resistant
Acinetobacter baumannii isolates, but were absent in ceftazidime-susceptible A. baumannii isolates. AmpC
over-expression resulted from insertion of ISAba1-like sequences upstream of blaampC. ISAba1 provided
strong promoter sequences, and it was demonstrated that the change in the ribosome binding site
sequence resulting from insertion of ISAba1 did not inﬂuence expression of the blaampC gene. Sequence
analysis revealed that AmpC sequences of A. baumannii isolates were almost identical and that ISAba1
elements had a high percentage of identity.
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INTRODUCTION
The most common mechanism of resistance to
b-lactams in Acinetobacter baumannii involves pro-
duction of a naturally occurring AmpC-type
cephalosporinase [1,2]. Insertion sequence (IS)
elements have been located upstream of the
blaampC gene of ceftazidime-resistant A. baumannii
[3,4], and it has been shown that IS1133-like
elements (designated ISAba1) provide promoter
sequences that enhance high-level expression of
the blaampC b-lactamase gene [3,4]. Insertion of
these elements upstream of the blaampC gene
provides new promoter sequences (Pout) for the
blaampC gene, which can replace the original
promoter sequences (Pori) that drive the expres-
sion of AmpC in the absence of any IS elements.
The insertion event results in a nucleotide change
inside the ribosome binding site (RBS) sequence
of the blaampC gene. The aim of the present study
was to study the detailed regulation of AmpC
expression by these IS elements, and to evaluate
the role of the nucleotide change in the RBS
sequence of the blaampC gene resulting from the
insertion event.
MATERIALS AND METHODS
Bacterial strains and plasmids
A. baumannii CLA-1 was isolated at the Hospital Biceˆtre
(K.-Biceˆtre, France) in 2001 (Table 1) [5]. Between 1998 and
2003, ten ceftazidime-susceptible and ﬁve ceftazidime-resistant
isolates of A. baumannii were collected from different hospitals
in Europe and Turkey (Table 1). These isolates were identiﬁed
by the API 20NE system (bioMe´rieux, Marcy l’Etoile, France).
Two additional reference strains were obtained from the
Institut Pasteur, Paris, France (Table 1). Escherichia coli strains
DH10B and JM109 were used for cloning experiments,
together with plasmid pACYC184 [6]. pCR-Blunt II-TOPO
(Invitrogen, Cergy Pontoise, France) was used for post-PCR
cloning and site-directed mutagenesis, and pKK232-8 (Amer-
sham Pharmacia Biotech, Saclay, France) was used as a
promoterless reporter gene. Details of the plasmids used in
this study are given in Table 2.
Antimicrobial agents and MIC determinations
The antimicrobial agents and their sources have been des-
cribed previously [7]. Antibiotic-containing disks were used
for detection of antibiotic susceptibility, with Mueller-Hinton
agar plates (Sanoﬁ Diagnostics Pasteur, Marnes-La-Coquette,
France) and a disk-diffusion assay (http://www.sfm.fr). MICs
were determined by agar dilution [7], with results interpreted
according to the guidelines of the Clinical and Laboratory
Standards Institute (CLSI, formerly NCCLS) [8].
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PCR ampliﬁcation
Primers preAB1 and preAB2, and preABprom + and preAB2
(Table 3) were used to amplify 1243-bp and 1507-bp fragments
containing the entire AmpC coding sequence without and with
the ISAba1 promoter sequences, respectively, using whole-cell
DNA from A. baumannii CLA-1 as the template. Primers Pori1
and Pori2 (Table 3) were used to amplify a 100-bp fragment
containing the -35 and -10 sequences of Pori, as well as the
original RBS (RBSori: TGAG) from the blaampC of A. baumannii
(Fig. 1); primers Pout1 and Pout2 (Table 3) were used to
amplify a 122-bp fragment containing the -35 and -10
sequences of Pout, as well as the RBS (RBSout: GGAG) as
modiﬁed by the insertion of ISAba1 (Fig. 1). PCRs were
performed as described previously [5].
Construction of reporter plasmids and site-directed
mutagenesis
The 1243-bp and 1507-bp PCR amplicons (see above) were
cloned in the EcoRV-restricted plasmid pACYC-184 to yield
plasmids pAB and pAB + (Table 2), respectively, which were
obtained and expressed in E. coli DH10B. The PCR amplicons
obtained with primers Pori1 and Pori2, and Pout1 and Pout2,
were cloned in the PCR cloning vector pCR-Blunt II-TOPO,
using the Zero Blunt TOPO PCR Cloning kit (Invitrogen,
Cergy Pontoise, France) as recommended by the manufacturer,
to yield plasmids TOPO(PoriRBSori) and TOPO(PoutRBSout)
(Table 2). The Quick Change site-directed mutagenesis kit
(Stragene, La Jolla, CA, USA) was used as recommended by
the manufacturer to substitute a T for a G in TOPO(PoriRBSori),
as in the RBS sequence modiﬁed by insertion of ISAba1, and a
G to a T in TOPO(PoutRBSout), as in the original RBS sequence
of the blaampC gene. TOPO(PoriRBSori) plasmid DNA was used
as template with primers Pori-mut1 and Pori-mut2 (Table 3) to
generate plasmid TOPO(PoriRBSout) (Table 2), and plasmid
TOPO(PoutRBSout) was used as template with primers Pout-
mut1 and Pout-mut2 (Table 3) to generate plasmid TOPO
(PoutRBSori) (Table 2). Plasmid DNA from the four recombinant
plasmids was digested with EcoRI, the corresponding inserts
were puriﬁed by gel electrophoresis, blunt-ended, and ligated
into SmaI-restricted pKK232-8 plasmid DNA (Amersham
Pharmacia Biotech). This latter plasmid carried a gene enco-
ding chloramphenicol acetyltransferase (CAT), the expression
Table 1. Origin and properties of Acinetobacter baumannii isolates examined as part of this study
Isolate Year of isolation Place of isolation b-Lactamase content
PCR detection
AmpC
over-expression
Ceftazidime
MIC values (mg ⁄L)ISAba1 ISAba1 ⁄ blaampC
CLA-1a 2001 Paris, France AmpC + OXA-40 + + + >512
RYC 52763 ⁄ 97b 1997 Madrid, Spain AmpC + OXA-24 + TEM-1 + + + >256
AYEc 2001 Valenciennes, France AmpC + VEB-1 + + + >512
Ama-1 2001 Paris, France AmpC + PER-1 + + + 512
S120 1998 Ankara, Turkey AmpC + + + 512
MK 8560 ⁄ 99 1999 Warsaw, Poland AmpC + + + 512
MK 8744 ⁄ 99 1999 Warsaw, Poland AmpC – – – 4
215d 1999 Montpellier, France AmpC + OXA-23 + – – 4
KB-1 1998 Paris, France AmpC – – – 4
KB-2 2003 Paris, France AmpC – – – 4
KB-3 2003 Paris, France AmpC – – – 4
KB-4 2003 Paris, France AmpC – – – 4
KB-5 2003 Paris, France AmpC – – – 4
KB-6 2003 Paris, France AmpC – – – 4
KB-7 2003 Paris, France AmpC – – – 4
KB-8 1999 Paris, France AmpC – – – 4
CIP 7034T 1969 Institut Pasteur collection AmpC – – – 2
CIP 70.10 1950 Institut Pasteur collection AmpC – – – 2
aData from [5].
bData from [2].
cData from [18].
dPersonal unpublished data.
Table 2. Plasmids used in this study
Plasmid Resistance Characteristics Origin
pACYC184 Cl, Tet Cloning vector New England Biolabs
pCR-Blunt II-TOPO Kan Post-PCR cloning vector Invitrogen
pKK232-8 Amp Reporter vector Pharmacia
pAB + Amp, Cl pACYC184 containing the entire blaampc and promoter Pout This study
pAB Am, Cl pACYC184 containing the entire blaampc This study
TOPO(PoriRBSori) Kan TOPO containing promoter Pori This study
TOPO(PoriRBSout) Kan TOPO containing promoter Pori mutated in its RBS This study
TOPO(PoutRBSout) Kan TOPO containing promoter Pout This study
TOPO(PoutRBSori) Kan TOPO containing promoter Pout mutated in its RBS This study
pKK232-8 (PoriRBSori) Amp, Cl pKK232-8 containing promoter Pori This study
pKK232-8 (PoriRBSout) Amp, Cl pKK232-8 containing promoter Pori mutated in its RBS This study
pKK232-8 (PoutRBSout) Amp, Cl pKK232-8 containing promoter Pout This study
pKK232-8 (PoutRBSori) Amp, Cl pKK232-8 containing promoter Pout mutated in its RBS This study
Cl, chloramphenicol; Tet, tetracycline; Kan, kanamycin; Amp, ampicillin.
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of which was measured to evaluate the strength of the cloned
promoters and the effect of the RBS changes. The ligation
products were used to transform competent cells of E. coli
JM109. The sequence of the inserted fragment was checked
using two primers from pKK232-8, pKK1 and pKK2 (Table 3)
[9], and an ABI 377 sequencer (Applied Biosystems, Foster City,
CA, USA).
Chloramphenicol acetyltransferase assays
Total protein concentration was measured by the Bio-Rad DC
protein assay (Bio-Rad, Ivry-Sur-Seine, France). CAT activity
was assayed using different recombinant plasmids and culture
extracts by a sandwich ELISA test performed in a microtitre
plate (CAT ELISA; Roche Applied Science, Meylan, France).
Each measurement of CAT enzyme activity was performed in
triplicate. E. coli JM109 and E. coli JM109 containing pKK232-8
without any insert were used as controls.
Southern blot experiments
Whole-cell DNA from A. baumannii isolates was digested with
EcoRI and transferred to a Nylon membrane (Hybond N+;
Amersham Pharmacia Biotech) as described previously [5].
The membrane was hybridised with a probe consisting of an
internal 389-bp fragment, ampliﬁed by primers ISAbaIa and
ISAbaIb (Table 3), which was speciﬁc for ISAba1. Southern
hybridisation was performed using the ECL nonradioactive
labelling and detection kit (Amersham Pharmacia Biotech) as
recommended by the manufacturer.
RESULTS AND DISCUSSION
Cloning and nucleotide sequence of blaampC and
ISAba1
A. baumannii clinical isolate CLA-1 (resistant to all
b-lactams) produced a carbapenem-hydrolysing
oxacillinase (OXA-40) and an AmpC-type
cephalosporinase [5]. While studying OXA-40,
recombinant clones expressing an AmpC-type
phenotype were obtained. A recombinant plas-
mid, pABC-1, conferring an AmpC-type b-lactam
resistance phenotype in E. coli, possessed a 2201-
bp insert. Following analysis of the nucleotide
and deduced amino-acid sequences, an AmpC
protein sequence was found that was identical
to that of another A. baumannii strain
(AbRYC52763 ⁄ 97), except for a single amino-acid
change (lysine to arginine at position 38) [2]. This
AmpC protein also shared 98% amino-acid iden-
tity with AmpC ABA-1 from A. baumannii. When
this gene was integrated into Oligella urethralis, b-
lactam resistance was conferred on the host [10].
An IS element, designated ISAba1, was identi-
ﬁed upstream of the blaampC gene. ISAba1 was
1180 bp long, with terminal inverted repeats (IR)
of 16 bp (Fig. 1), and belongs to the IS4 family,
according to the IS nomenclature proposed by
Chandler and Mahillon [11]. The sequence of
ISAba1 is available from the IS Biotoul website
(http://www-is.biotoul.fr) with GenBank acces-
sion number AY758396. The inverted repeat left
(IRL) is located just 9 bp upstream of the start
codon of the ampC gene (Fig. 1). The transposition
which occurred in A. baumannii CLA-1 generated
a 9-bp duplication of the target sequence (Fig. 1).
This is a likely reason for the ATG start codon
being located immediately downstream of the
direct repeat (DR) generated by the transposition
event (Fig. 1). It is noteworthy that this duplica-
tion has modiﬁed the RBS by a single base,
changing TGAG to GGAG (Fig. 1; position 1271–
1274).
ISAba1 is very similar to the IS1133-like element
located upstream of the aminoglycoside resist-
ance gene aacC2 identiﬁed in an A. baumannii
isolate (ﬁve nucleotide changes) [12], or that
found upstream of the blaampC gene identiﬁed in
other A. baumannii isolates (ﬁve nucleotide chan-
ges) [3,4], and also to the partial sequence found
upstream of the phaBAC sequence of A. baumannii
RA3849 which encodes an aceto acetyl coenzyme
A reductase (three nucleotide changes) [13]. The
main difference was that ISAba1 had a single
nucleotide deletion at position 584–585 (T-G at
position 686–687 in Fig. 1, instead of TGG),
compared with the IS1133-like element, that gave
rise to a truncated transposase protein and over-
lapping of two open reading frames (ORFs)
(Fig. 1).
ISAba1 shares 43% identity with ISDra1 from
Deinococcus radiodurans R1, for which the ORF is a
327 amino-acid protein after taking the frameshift
into account [14]. Sequences separated by 17 bp,
Table 3. Sequences of primers designed for this study
Primer Sequence (5¢–>3¢)
preABprom + GACCTGCAAAGAAGCGCTGC
preAB1 ACAGAGGAGCTAATCATGCG
preAB2 GTTCTTTTAAACCATATACC
Pori1 CCATGTGCTATAACAACATA
Pori2 TGTCGTGTACAGAGGATTAG
Pout1 ATAAGATATAAGTCATTGAG
Pout2 TTTTTAAATCGCATGATTAG
Pori-mut1 GCATCTTTCTTTTTAAATAATTTAGGA
GCTAATCCTCTGTACACG
Pori-mut2 CGTGTACAGAGGATTAGCTCCTAAATTAT
TTAAAAAGAAAGATGC
Pout-mut1 CGTGTACAGATGAGCTAATCATGCG
Pout-mut2 CGCATGATTAGCTCATCTGTACACG
pKK1 TGCGAAGCAACGGCCCGG
pKK2 AAGCTTGGCTGCAGGTCGA
ISAba1a ATGCAGCGCTTCTTTGCAGG
ISAba1b AATGATTGGTGACAATGAAG
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constituting a Pin promoter for ORF1 (189 amino-
acids) expression, were identiﬁed (-35 (TTGAAA)
and -10 (TTTTCT); Fig. 1). ORF2 is a 178 amino-
acid protein if the valine codon, located at
position 644–646 in Fig. 1, is considered as the
initiation codon. However, it is likely that a
frameshift may occur in ISAba1 in the overlapping
region, giving rise to a unique and probably
functional transposase protein, as observed for
other IS elements such as IS911, which has two
consecutive ORFs [11,15,16]. A change in reading
frame, when transcribing the orf1 gene, could
allow translation to continue in the orf2 frame,
giving rise to a protein comprising most of the
Fig. 1. Nucleotide sequence of the insertion sequence upstream of blaampC. The deduced amino-acid sequence is
designated in a single letter code below the nucleotide sequence, direct repeat (DR) sequences are underlined, and inverted
repeat sequences (IRR and IRL) are in grey. The frameshift site is double-underlined. The stars indicate stop codons. The
-35 and -10 motifs of promoters are indicated. Pin is the promoter of the orf1 transposase gene in ISAba1, Pout the promoter
of blaampC provided by ISAba1, and Pori the putative host-cell promoter driving the expression of blaampC in the absence of
ISAba1. The original ribosome binding site of blaampC, and that identiﬁed following insertion of ISAba1, are indicated in
bold characters.
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ORF1 and ORF2 polypeptides which may act as a
transposase [15,17].
The sequence that allows backward shifting of
the ribosome is an heptanucleotide that might
correspond to the A AAA AAAmotif identiﬁed in
ISAba1 at positions 654–660 (T TTT TTT in Fig. 1)
[14,16]. This frameshift may occur at a low
frequency, leading to low-level expression of the
functional transposase and thus to relative stabil-
ity of this IS element.
Cloning of the blaampC gene with or without
the Pout promoter
The -35 and -10 sequences (TTAGAA and
TTATTT, respectively) separated by 16 bp, which
are able to constitute a Pout promoter, were
identiﬁed in the right-hand boundary of ISAba1
[3,4], being located 41 bp upstream of the start
codon of the blaampC gene where they probably
enhance its expression (Fig. 1) [3,4]. Antibiotic
susceptibility testing revealed that E. coli DH10B
(pAB+), with the insert containing the ISAba1-
mediated promoter sequences, had reduced sus-
ceptibility to most b-lactams compared with
E. coli DH10B (pAB) (Table 4), including ticarcil-
lin, piperacillin and aztreonam.
Role of the nucleotide change in the RBS
sequence of the blaampC gene
On the right-hand boundary of ISAba1, other -35
(TTGTTA) and -10 (TTTTTA) sequences, separ-
ated by 18 bp, were identiﬁed in A. baumannii
CLA-1. These probably correspond to the original
Pori promoter sequences of AmpC, and drive its
expression in the absence of ISAba1 (Fig. 1). Since
ISAba1 insertion gave rise to a T to G nucleotide
change in the RBS sequence (Fig. 1; positions
1271–1274) of a sensitive strain of A. baumannii,
the effect of this nucleotide change on expression
at the level of translation was analysed.
A ten-fold increase in CAT activity was ob-
served when Pout was present upstream of ampC
when compared with the Pori promoter sequences
(Table 5). However, no difference in CAT activity
was observed between RBSori and RBSout.
The results of the CAT assays conﬁrmed that
ISAba1 supplied strong promoter sequences [3,4]
and indicated that the change in the RBS sequence
resulting from the insertion of ISAba1 did not
inﬂuence the expression of blaampC.
Distribution of ISAba1
As ISAba1 located upstream of blaampC was
involved in the increased level of b-lactam resist-
ance, the presence of similar sequences was
investigated by PCR in A. baumannii isolates with
different b-lactam resistance patterns (Table 1).
Sixteen clinical isolates and two reference strains
of A. baumannii of different origins were analysed,
including 12 ceftazidime-susceptible and six ceft-
azidime-resistant isolates (according to CLSI
guidelines [8]) (Table 1). A previous study had
demonstrated by pulsed-ﬁeld gel electrophoresis
[18] that none of the isolates were clonally related
[19]. PCR amplicons were obtained with primers
ISAba1a and ISAba1b (Table 3), which amplify an
internal 389-bp fragment of ISAba1, with seven
isolates, including the six ceftazidime-resistant
isolates and A. baumannii 215 (which produces
OXA-23), while negative results were obtained
with all the ceftazidime-susceptible isolates
Table 4. MICs of b-lactams for Escherichia coli DH10B and
E. coli DH10B clones harbouring recombinant plasmids
pAB + and pAB containing the entire AmpC coding
sequence with or without promoter Pout
b-Lactam(s)
MICs (mg ⁄L)
E. coli DH10B (pAB+)
E. coli DH10B
(pAB)
E. coli
DH10B
Amoxycillin >512 >512 4
Amoxycillin + CLA >512 >512 4
Ticarcillin 64 8 4
Piperacillin 64 8 2
Piperacillin + TZB 32 4 2
Cephalothin 256 128 4
Cefuroxime 256 128 4
Cefoxitin 32 16 4
Ceftazidime 64 16 0.06
Cefotaxime 32 8 0.06
Cefepime 0.12 0.06 0.06
Cefpirome 0.25 0.12 0.06
Moxalactam 0.5 0.12 0.06
Aztreonam 16 0.25 0.12
Imipenem 0.25 0.12 0.06
CLA, clavulanic acid at a ﬁxed concentration of 2 mg ⁄L; TZB, tazobactam at a ﬁxed
concentration of 4 mg ⁄L.
Table 5. Comparison of the strength of the ampC promot-
ers Pori and Pout, combined with the two different ribosome
binding site sequences
Plasmid used to transform E. coli JM109 CAT activity (pg/lg)a
None 3 ± 1
pKK232-8 3 ± 1
pKK232-8(PoriRBSori) 47 ± 8
pKK232-8(PoriRBSout) 48 ± 8
pKK232-8(PoutRBSori) 398 ± 16
pKK232-8(PoutRBSout) 502 ± 16
aMean ± standard deviation of three determinations of CAT activity.
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(Table 1). Using the preABprom+ and preAB2
primers, which anneal upstream of blaampC in
ISAba1 (Table 3), positive results were obtained
for the six ceftazidime-resistant isolates, but not
for the blaOXA-23-positive A. baumannii isolate. In
this latter strain, the IS element identiﬁed had
99% nucleotide homology with ISAba1 over the
972-bp sequence upstream of blaOXA-23, with the
same overlapping of two ORFs. Thus, as suggest-
ed by Segal et al. [20], ISAba1 might also play a
role in expression and acquisition of various
antibiotic resistance genes, such as carbapenem-
hydrolysing oxacillinase genes.
Using a 389-bp internal probe for ISAba1,
Southern blot experiments were negative for the
ceftazidime-susceptible A. baumannii isolates, but
yielded between one and nine positive signals
with the ceftazidime-resistant isolates and the
blaOXA-23-positive A. baumannii isolate (Fig. 2).
Thus, the ceftazidime-resistant isolates possessed
several copies of ISAba1, one copy being located
upstream of the blaampC gene. While this work
was in progress, Segal et al. [20] also identiﬁed
several copies of ISAba1 in Acinetobacter isolates
containing this element.
Interestingly, ISAba1 was identiﬁed upstream
of the blaampC gene of A. baumannii isolates
expressing PER-1 and VEB-1 extended-spectrum
b-lactamases, indicating a dual mechanism for
ceftazidime resistance, involving both AmpC
hyper-production caused by ISAba1 insertion
and acquisition of a broad-spectrum b-lactamase
gene. Whereas inducible AmpC expression has
been reported for most AmpC-positive Gram-
negative bacterial species [6], this is not the case
for A. baumannii. Induction experiments, perf-
ormed with imipenem or cefoxitin as inducers
and cephalothin as substrate [21], conﬁrmed the
absence of AmpC induction in A. baumannii.
These results are consistent with the absence of
a LysR-type regulatory gene located upstream of
the blaampC gene.
As reported for AmpC genes from Pseudomonas
aeruginosa [22,23], the AmpC sequences from
different isolates of A. baumannii were almost
identical (no more than two amino-acid substitu-
tions), regardless of the level of b-lactamase
expression or the presence of ISAba1. Sequence
analysis of the seven ISAba1 elements also
revealed a high degree of identity (99%), with
none of the nucleotide changes occurring in the
area of the putative frameshift site.
The association between ISAba1 and blaampC or
blaOXA-23 adds to the diversity of IS elements as
sources of b-lactamase expression (10, 18, 24–34).
Further work should determine whether isolates
of A. baumannii can be delineated into two sub-
species, with the ﬁrst being ceftazidime-suscept-
ible and lacking an ISAba1-like sequence, and the
second being ceftazidime-resistant as a result of
the insertion of ISAba1, which then became
disseminated throughout the chromosome.
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Fig. 2. EcoRI-restricted genomic
DNA from the 18 Acinetobacter
baumannii isolates following hybrid-
isation with a probe consisting of an
internal 389-bp fragment of ISAba1.
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